Recent Updates
Recently added Catalysts
TNDM Negative Sentiment Score: 25/100

TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating potential claims against Tandem Diabetes Care, Inc. related to a class action filed on September 8, 2023. The investigation focuses on allegations that Tandem's board may have breached fiduciary duties by providing misleading revenue projections for 2022. Following a significant downward revision in sales forecasts attributed to increased competition and macroeconomic factors, Tandem's stock price fell sharply. The firm encourages long-term stockholders to reach out for more information regarding their rights.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action complaint has been filed against Tandem, alleging misleading information provided to investors.
  • Tandem's projected sales were significantly revised downward, impacting investor trust.
  • The stock price experienced a dramatic decline of over 30% following revised earnings forecasts.

Full Press Release Details

NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) on behalf of long-term stockholders following a class action complaint that was filed against Tandem on September 8, 2023 with a Class Period from August 3, 2022 to November 2, 2022. Our investigation concerns whether the board of directors of Tandem have breached their fiduciary duties to the company.
The filed complaint alleges that defendants provided investors with material information concerning Tandem’s projected revenue and sales for the year ending 2022. On August 2, 2022, Tandem estimated annual sales “to be in the range of $835 million to $845 million, which represents an annual growth of 19 percent to 20 percent compared to 2021.” Defendants provided these statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts.
According to the complaint, the truth emerged on November 2, 2022, when Tandem, in an investment call and Form 8-K filing, revised its 2022 forecast downward to $800 to $805 million. Reasons stated for the scale back included increased competition in the diabetes care sector, complications due to the COVID pandemic, and macroeconomic factors such as inflation. Investors and analysts reacted immediately to Tandem’s revised guidance. The price of Tandem’s common stock declined dramatically. On November 2, 2022, Tandem closed at $51.34; however, on November 3, 2022, Tandem closed at $35.72 – a one-day decline of 30.4%.
If you are a long-term stockholder of Tandem, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is Tandem Diabetes Care being investigated for?

Tandem Diabetes Care is under investigation for potential claims regarding breaches of fiduciary duties by its board of directors.

What did Tandem estimate for its 2022 annual sales?

Tandem estimated its 2022 annual sales to be between $835 million and $845 million.

When did Tandem revise its sales forecast downwards?

Tandem revised its 2022 sales forecast downwards on November 2, 2022.

How much did Tandem's stock drop on November 3, 2022?

Tandem's stock dropped by 30.4%, closing at $35.72 on November 3, 2022.

How can long-term stockholders learn more about the claims?

Long-term stockholders can contact Bragar Eagel & Squire by email or phone for more information.

Last updated: Apr 24, 2024